Registered number
14632770
Layanson Pharma Ltd
Report and Unaudited Accounts
28 February 2025
Layanson Pharma Ltd
Report and accounts
Contents
Page
Company information 1
Directors' report 2
Chartered Accountants' report 3
Profit and loss account 4
Balance sheet 5
Statement of changes in equity 6
Notes to the accounts 7
Layanson Pharma Ltd
Company Information
Directors
Adedamola Layade
Accountants
CTMP Accountants Ltd
Chartered Accountants
838 Wickham Road
Croydon
CR0 8ED
Registered office
3 Bramley Road
Thornbury
United Kingdom
BS35 1EY
Registered number
14632770
Layanson Pharma Ltd
Registered number: 14632770
Directors' Report
The directors present their report and accounts for the year ended 28 February 2025.
Principal activities
The company's principal activity during the year continued to be that of a pharmacy.
Directors
The following persons served as directors during the year:
Adedamola Layade
Small company provisions
This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.
This report was approved by the board on 9 October 2025 and signed on its behalf.
Adedamola Layade
Director
Layanson Pharma Ltd
Chartered Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of Layanson Pharma Ltd for the year ended 28 February 2025
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Layanson Pharma Ltd for the year ended 28 February 2025 which comprise of the Profit and Loss Account, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at
www.icaew.com/en/members/regulations-standards-and-guidance
Our work has been undertaken in accordance with ICAEW Technical Release 07/16 AAF.
CTMP Accountants Ltd
Chartered Accountants
838 Wickham Road
Croydon
CR0 8ED
9 October 2025
Layanson Pharma Ltd
Profit and Loss Account
for the year ended 28 February 2025
2025 2024
£ £
Turnover 1,269,898 686,635
Cost of sales (846,303) (401,344)
Gross profit 423,595 285,291
Administrative expenses (378,187) (187,369)
Operating profit 45,408 97,922
Interest receivable 149 -
Interest payable (45,015) (273)
Profit before taxation 542 97,649
Tax on profit (72,181) (39,253)
(Loss)/profit for the financial year (71,639) 58,396
Layanson Pharma Ltd
Registered number: 14632770
Balance Sheet
as at 28 February 2025
Notes 2025 2024
£ £
Fixed assets
Intangible assets 3 139,333 181,133
Tangible assets 4 211,136 157,011
350,469 338,144
Current assets
Stocks 53,000 30,000
Debtors 5 196,524 284,654
Cash at bank and in hand 90,159 23,318
339,683 337,972
Creditors: amounts falling due within one year 6 (309,972) (296,858)
Net current assets 29,711 41,114
Total assets less current liabilities 380,180 379,258
Creditors: amounts falling due after more than one year 7 (330,197) (281,608)
Provisions for liabilities (71,525) (39,253)
Net (liabilities)/assets (21,542) 58,397
Capital and reserves
Called up share capital 1 1
Profit and loss account (21,543) 58,396
Shareholders' funds (21,542) 58,397
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Adedamola Layade
Director
Approved by the board on 9 October 2025
Layanson Pharma Ltd
Statement of Changes in Equity
for the year ended 28 February 2025
Share Share Re- Profit Total
capital premium valuation and loss
reserve account
£ £ £ £ £
At 1 February 2023 - - - - -
Profit for the period 58,396 58,396
Shares issued 1 - 1
At 29 February 2024 1 - - 58,396 58,397
At 1 March 2024 1 - - 58,396 58,397
Loss for the financial year (71,639) (71,639)
Dividends (8,300) (8,300)
At 28 February 2025 1 - - (21,543) (21,542)
Layanson Pharma Ltd
Notes to the Accounts
for the year ended 28 February 2025
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Intangible fixed assets
Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Freehold buildings over 50 years
Leasehold land and buildings over the lease term
Plant and machinery over 5 years
Fixtures, fittings, tools and equipment over 5 years
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Leased assets
A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2025 2024
Number Number
Average number of persons employed by the company 19 10
3 Intangible fixed assets £
Goodwill:
Cost
At 1 March 2024 209,000
At 28 February 2025 209,000
Amortisation
At 1 March 2024 27,867
Provided during the year 41,800
At 28 February 2025 69,667
Net book value
At 28 February 2025 139,333
At 29 February 2024 181,133
Goodwill is being written off in equal annual instalments over its estimated economic life of 5 years.
4 Tangible fixed assets
Plant and machinery etc Motor vehicles Total
£ £ £
Cost
At 1 March 2024 181,167 - 181,167
Additions 1,057 79,750 80,807
At 28 February 2025 182,224 79,750 261,974
Depreciation
At 1 March 2024 24,156 - 24,156
Charge for the year 31,666 (4,984) 26,682
At 28 February 2025 55,822 (4,984) 50,838
Net book value
At 28 February 2025 126,402 84,734 211,136
At 29 February 2024 157,011 - 157,011
5 Debtors 2025 2024
£ £
Trade debtors 101,078 268,098
Other debtors 95,446 16,556
196,524 284,654
6 Creditors: amounts falling due within one year 2025 2024
£ £
Bank loans and overdrafts 53,694 53,694
Obligations under finance lease and hire purchase contracts 18,346 -
Trade creditors 194,439 148,721
Taxation and social security costs 42,694 102
Other creditors 799 94,341
309,972 296,858
7 Creditors: amounts falling due after one year 2025 2024
£ £
Bank loans (secured) 272,560 281,608
Obligations under finance lease and hire purchase contracts 57,637 -
330,197 281,608
8 Loans 2025 2024
£ £
Creditors include:
Instalments falling due for payment after more than five years 76,832 76,832
Secured bank loans 345,302 345,302
Loans are secured by fixed and flaoting charge on the assets of the company.
9 Other information
Layanson Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
3 Bramley Road
Thornbury
United Kingdom
BS35 1EY
Layanson Pharma Ltd 14632770 false 2024-03-01 2025-02-28 2025-02-28 VT Final Accounts July 2024 14632770 2023-02-01 2024-02-29 14632770 core:ShareCapital 2023-02-01 2024-02-29 14632770 core:SharePremium 2023-02-01 2024-02-29 14632770 core:WithinOneYear 2024-02-29 14632770 core:AfterOneYear 2024-02-29 14632770 core:ShareCapital 2024-02-29 14632770 core:RetainedEarningsAccumulatedLosses 2024-02-29 14632770 2023-01-31 14632770 core:ShareCapital 2023-01-31 14632770 core:SharePremium 2023-01-31 14632770 core:OtherReservesSubtotal 2023-01-31 14632770 core:RetainedEarningsAccumulatedLosses 2023-01-31 14632770 2024-03-01 2025-02-28 14632770 bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 14632770 bus:AuditExemptWithAccountantsReport 2024-03-01 2025-02-28 14632770 bus:Director1 2024-03-01 2025-02-28 14632770 core:RetainedEarningsAccumulatedLosses 2024-03-01 2025-02-28 14632770 bus:AllOrdinaryShares core:RetainedEarningsAccumulatedLosses 2024-03-01 2025-02-28 14632770 1 2024-03-01 2025-02-28 14632770 2 2024-03-01 2025-02-28 14632770 core:Goodwill 2024-03-01 2025-02-28 14632770 core:PlantMachinery 2024-03-01 2025-02-28 14632770 core:Vehicles 2024-03-01 2025-02-28 14632770 countries:England 2024-03-01 2025-02-28 14632770 bus:FRS102 2024-03-01 2025-02-28 14632770 bus:FilletedAccounts 2024-03-01 2025-02-28 14632770 2025-02-28 14632770 core:WithinOneYear 2025-02-28 14632770 core:AfterOneYear 2025-02-28 14632770 core:ShareCapital 2025-02-28 14632770 core:RetainedEarningsAccumulatedLosses 2025-02-28 14632770 core:SharePremium 2025-02-28 14632770 core:OtherReservesSubtotal 2025-02-28 14632770 core:Goodwill 2025-02-28 14632770 core:PlantMachinery 2025-02-28 14632770 core:Vehicles 2025-02-28 14632770 2024-02-29 14632770 core:SharePremium 2024-02-29 14632770 core:OtherReservesSubtotal 2024-02-29 14632770 core:Goodwill 2024-02-29 14632770 core:PlantMachinery 2024-02-29 14632770 core:Vehicles 2024-02-29 iso4217:GBP xbrli:pure